Saturday 17 October 2026
Export ZBIO’s income statement to Excel — free account
Zenas BioPharma, Inc.
ZBIO Healthcare Biotechnology
Zenas BioPharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, up 100.0% from fiscal 2024. In the quarter to June 2026, EPS fell 41.6% and free cash flow fell 37.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
24.67
0.73
−2.87%
Follow ZBIO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(68.33%) | (136.22%) | (137.11%) | (199.04%) | |
| (52.35%) | (100.25%) | (78.63%) | (97.39%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(77.74%) | (130.91%) | (63.55%) | (82.38%) | |
Free Cash Flow per Share |
(3.76) | (3.85) | (3.78) | (3.58) | |
Free Cash Flow |
(158.56) | (172.35) | (210.48) | (225.97) | |
Capital Expenditures |
(0.09) | (0.02) | 0.00 | 0.00 | |
| Other line items | |||||
Cash ROIC |
(28.30%) | (25.96%) | (15.00%) | (17.67%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.83 | 0.46 | 0.50 | 0.47 | |
Depreciation/Fixed assets |
1.58 | 1.65 | 1.39 | 1.35 | |
Capex/Depreciation |
(1.16) | (0.32) | (0.05) | (0.06) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.76) | (3.85) | (3.78) | (3.58) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates